Key points are not available for this paper at this time.
Real-time high-quality data on the performance of digital health applications is needed for feedback-led optimization and to ensure safety and performance, particularly if they will have on-market updates. Developers must verify that applications accurately and consistently fulfill their intended purpose in real-world use. In particular, new thinking from regulators recognizes the importance of monitoring real-world performance. It is acknowledged that real-world data can deliver information from wider patient populations than are generally included in controlled studies, and in certain circumstances, this can enable extensions of the application's intended purpose. Proactive postmarket surveillance surveys are an important source of real-world data that are distinct from clinical investigations but may vary in quality and, if inappropriately designed, can be subject to uncontrolled bias. We aimed to describe the practice of real-world data gathering through patient-reported and clinician-reported outcomes and high-quality surveys and identify challenges, uncertainties, and health policy gaps.
Gilbert et al. (Sun,) studied this question.